Evidence map›Paper›PMID 37103093›Full record

Observational studyIn vivo (Athens, Greece)

Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.

Nobuyuki Yorioka, Tadashi Namisaki, Akihiko Shibamoto, Junya Suzuki, Takahiro Kubo, Satoshi Iwai, Fumimasa Tomooka, Misako Tanaka, Soichi Takeda, Yuki Fujimoto and 14 more

Open access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Drainage of ascites in cirrhosis.World journal of hepatology · 2024
    Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Nobuyuki YoriokaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Tadashi NamisakiDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan; tadashin@naramed-u.ac.jp.
Akihiko ShibamotoDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Junya SuzukiDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Takahiro KuboDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Satoshi IwaiDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Fumimasa TomookaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Misako TanakaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Soichi TakedaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Yuki FujimotoDivision of Endoscopy, Nara Medical University, Kashihara, Japan.
Masahide EnomotoDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Koji MuarataDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Takashi InoueDepartment of Evidence-Based Medicine, Nara Medical University Hospital, Kashihara, Japan.
Yuki TsujiDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Yukihisa FujinagaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Norihisa NishimuraDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Koh KitagawaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Hiroaki TakayaDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Kosuke KajiDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Hideto KawarataniDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Takemi AkahaneDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Akira MitoroDivision of Endoscopy, Nara Medical University, Kashihara, Japan.
Masaharu YamazakiCentral Clinical Laboratory, Nara Medical University Hospital, Kashihara, Japan.
Hitoshi YoshijiDepartment of Gastroenterology, Nara Medical University, Kashihara, Japan.
Nara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe management of refractory ascites is critical for the treatment of patients with decompensated cirrhosis. This study aimed to evaluate the feasibility and safety of cell-free and concentrated ascites reinfusion therapy (CART) in patients with cirrhosis and refractory ascites, with a focus on changes in coagulation and fibrinolytic factors in ascitic fluid following CART. PATIENTS AND

methodsThis was a retrospective cohort study including 23 patients with refractory ascites undergoing CART. Serum endotoxin activity (EA) before and after CART and the levels of coagulation and fibrinolytic factors and proinflammatory cytokines in original and processed ascitic fluid were measured. The Ascites Symptom Inventory-7 (ASI-7) scale was used for subjective symptom assessment before and after CART.

resultsBody weight and waist circumference significantly decreased after CART, whereas serum EA did not significantly change after CART. Similar to the previous reports, ascitic fluid concentrations of total protein, albumin, high-density lipoprotein cholesterol, γ-globulin, and immunoglobulin G levels were significantly increased after CART; mild elevations in body temperature and interleukin 6 and tumor necrosis factor-alpha levels in ascitic fluid were also observed. Importantly, the levels of antithrombin-III, factor VII, and X, which are useful for patients with decompensated cirrhosis, were markedly increased in the reinfused fluid during CART. Finally, the total ASI-7 score was significantly lower following CART, compared with the pre-CART score.

conclusionCART is an effective and safe approach for the treatment of refractory ascites that allows the intravenous reinfusion of coagulation and fibrinolytic factors in the filtered and concentrated ascites.

Indexed as

AscitesAscitic FluidHumansJapanLiver CirrhosisRetrospective Studiescell-free and concentrated ascites reinfusion therapycirrhosiscoagulationfibrinolyticRefractory ascites

Identifiers

PMID37103093
PMCPMC10188040
OpenAlexW4367174588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.